Remarkably, the vesiculation of the CTLA-4 inhibitor in PEGylated liposomes led to a 5-day increase in the median survival time (MST), a tumor growth delay (TGD) of 11.8%, a higher effector T cells (Teff) to regulatory T cells (Treg) ratio and a greater CD8 + T cells number [22]. The gene discussed is CD8A; the disease is neoplasm.